Regulus Acquires IP Related to miR-21 Modulation
May 27, 2010
Regulus Acquires IP Related to miR-21 Modulation
According to the company, the miRNA has been shown to be dysregulated in mouse models of cardiac disease and fibrosis, and "antagonizing miR-21 with therapeutic oligonucleotides … inhibits fibrosis and attenuates cardiac function in such models."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Regulus Inks miRNA Drug R&D Deal with Sanofi-Aventis Worth up to $750M
June 24, 2010 / Gene Silencing News - Regulus Says USPTO Allows Claims in miRNA-Related Patent Application
October 29, 2009 / Gene Silencing News - Japanese Patent Office to Grant miRNA Patent from Tuschl-III Family
September 24, 2009 / Gene Silencing News - Regulus Receives Notice of Allowance on miRNA Antagonist Patent Application
August 13, 2009 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News